未知生产厂商
Dendritic cells (DCs) can be derived and differentiated from peripheral blood mononuclear cells in the presence of specific cytokines and growth factors. These cells are then loaded with antigens produced by a virus or tumor cell and administered as a vaccine. Dendritic Cells (DCs) are showing potential as natural adjuvants for vaccines due to their ability to both prime and boost cell responses; they are considered the most powerful antigen-presenting cells, and are able to present antigens through costimulatory signals required for activation of CD4+ and CD8+ T-cells. DC-based vaccines are currently used in cancer therapeutics, and are being tested for COVID-19. The rationale is that loading a DC cell with SARS-Cov-2 antigens and administering it as a vaccine can induce a more prolific immune response. This vaccine was developed and tested by Beijing TIL Therapeutics. As of May 2020, the company is pursuing a human clinical trial (ChiCTR2000033003) to test the safety and immunogenicity of the vaccine.
Dendritic cells (DCs) can be derived and differentiated from peripheral blood mononuclear cells in the presence of specific cytokines and growth factors. These cells are then loaded with antigens produced by a virus or tumor cell and administered as a vaccine. Dendritic Cells (DCs) are showing potential as natural adjuvants for vaccines due to their ability to both prime and boost cell responses; they are considered the most powerful antigen-presenting cells, and are able to present antigens through costimulatory signals required for activation of CD4+ and CD8+ T-cells. DC-based vaccines are currently used in cancer therapeutics, and are being tested for COVID-19. The rationale is that loading a DC cell with SARS-Cov-2 antigens and administering it as a vaccine can induce a more prolific immune response. This vaccine was developed and tested by Beijing TIL Therapeutics. As of May 2020, the company is pursuing a human clinical trial (ChiCTR2000033003) to test the safety and immunogenicity of the vaccine.
